These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23166563)

  • 1. Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups.
    Dell'osso B; Camuri G; Dobrea C; Buoli M; Serati M; Altamura AC
    Clin Pract Epidemiol Ment Health; 2012; 8():120-5. PubMed ID: 23166563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study.
    Dell'osso B; Arici C; Dobrea C; Camuri G; Benatti B; Altamura AC
    Neuropsychiatr Dis Treat; 2013; 9():205-9. PubMed ID: 23429980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
    Carter NJ; McCormack PL
    CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder.
    Muscatello MRA; Zoccali RA; Pandolfo G; Mangano P; Lorusso S; Cedro C; Battaglia F; Spina E; Bruno A
    Front Psychiatry; 2019; 10():772. PubMed ID: 31749717
    [No Abstract]   [Full Text] [Related]  

  • 5. Duloxetine in the treatment of generalized anxiety disorder.
    Wright A; Vandenberg C
    Int J Gen Med; 2009 Dec; 2():153-62. PubMed ID: 20360899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine for the treatment of generalized anxiety disorder: a review.
    Khan AY; Macaluso M
    Neuropsychiatr Dis Treat; 2009; 5():23-31. PubMed ID: 19557096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of duloxetine in the treatment of anxiety disorders.
    De Berardis D; Serroni N; Carano A; Scali M; Valchera A; Campanella D; D'Albenzio A; Di Giuseppe B; Moschetta FS; Salerno RM; Ferro FM
    Neuropsychiatr Dis Treat; 2008 Oct; 4(5):929-35. PubMed ID: 19183783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists.
    Alvarez-Mon MA; García-Montero C; Fraile-Martinez O; Quintero J; Fernandez-Rojo S; Mora F; Gutiérrez-Rojas L; Molina-Ruiz RM; Lahera G; Álvarez-Mon M; Ortega MA
    Brain Sci; 2023 Feb; 13(2):. PubMed ID: 36831876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
    Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
    J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.
    Mancini M; Perna G; Rossi A; Petralia A
    Expert Opin Pharmacother; 2010 May; 11(7):1167-81. PubMed ID: 20402555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine.
    Rodrigues-Amorim D; Olivares JM; Spuch C; Rivera-Baltanás T
    Front Psychiatry; 2020; 11():554899. PubMed ID: 33192668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N; Schennach R; Riedel M; Möller HJ
    Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of duloxetine in treatment-refractory men with posttraumatic stress disorder.
    Walderhaug E; Kasserman S; Aikins D; Vojvoda D; Nishimura C; Neumeister A
    Pharmacopsychiatry; 2010 Mar; 43(2):45-9. PubMed ID: 20108200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and Associated Features of Anxiety Disorder Comorbidity in Bipolar Disorder: A Meta-Analysis and Meta-Regression Study.
    Yapici Eser H; Kacar AS; Kilciksiz CM; Yalçinay-Inan M; Ongur D
    Front Psychiatry; 2018; 9():229. PubMed ID: 29997527
    [No Abstract]   [Full Text] [Related]  

  • 19. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.